In the study of Seo and colleagues, in 2014, there were two HER2 assessment cohorts: the first cohort involved 365 patients with CRC, and HER2 overexpression was found in eight subjects (2.2%). The gene discussed is ERBB2; the disease is colorectal carcinoma.